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Abstract 
 
Background: Discovery of new biomarker represent the greatest promise for the detection and 
management of cancer. Although progress in cancer biology has been rapid during the past few 
years, the complete understanding of molecular basis for cancer initiation, progression and 
efficacious treatments is still lacking. In this context, the application of proteomic strategies is now 
holding a focal position. The main reason is that proteins are the functional players that drive cancer 
phenotypes. Among cancers, breast and colon represent the most frequent forms. The evolution of 
these type of cancer are not easily predictable since there are several types that behave differently 
among patients. The biological heterogeneity is consistent with observed varied responses to 
therapies across patients, also. On the other hand, drug delivery is an emergent field focused on 
targeting drugs to a desirable group of cells, in order to minimize undesirable side-effects and 
maximize the therapeutic activity. Metallic nanoparticles, in particular silver nanoparticles (Ag-
NPs) exhibit low toxicity to mammalian cells (Mahapatra and Karak, 2008) and are good candidate 
as smart therapeutics. Based on these evidences, the first part of the study was aimed to discover 
new potential protein biomarkers in breast and colon cancer tissues and sera, using proteomic 
techniques, useful as diagnostic and prognostic factors in vivo. The second part of the study was 
focused on the in vitro cytotoxic effects of silver nanoparticles Ag-NPs embedded on Klebsiella 
Oxytoca DSM29614 (KO) Exopolysaccaride (EPS), produced in aerobic versus anaerobic 
conditions. 
Methods: Diagnostic biomarkers in breast and colon cancer: Taken advantage from previous 
results by the proteomic analysis performed on 13 breast cancer tissues and their matched non-
tumoral adjacent tissues (Pucci-Minafra et al., 2007), we first analyze by 2D-DIGE pool of both 
breast and colon cancer tissues extracts compared to the matched pool of non tumoral adjacent 
tissues extracts. Differentially expressed proteins, identified by Maldi-TOF/TOF, were functionally 
clustered. We also investigate the activity levels of MMP-2 and MMP-9 in breast and colon tissues 
as well as in sera of the same patients.  
Prognostic biomarkers in breast and colon cancer: In order to identity putative proteomic 
signatures for colorectal cancer (CRC) metastasis, a comparative profiling of a colon cancer tissue 
paired with the non tumoral adjacent mucosa and with the liver metastasis from the same patient 
was performed. A three-step approach (normal versus tumoral versus metastasis) was used to select 
unique proteins involved in liver metastasis. For breast cancer, a large proteomic investigation 
performed on a large sample set of breast cancer patients (Cancemi et al., 2010, 2012), pointed the 
important role of S100 protein members in breast cancer progression. Using on line tools, for 
instance GOBO and breast cancer Kaplan Meir-plotter we assessed gene expression levels and 
clinical correlations of S100 proteins in breast patients. 
Cytotoxic effects of silver nanoparticles biosynthesized from KO (Ag-NPs-EPS) in SK-BR3 breast 
cancer cell line: We monitored cell proliferation inhibition rate by MTT assay, morphological 
changes and proteomic modulation. 
Results: Diagnostic biomarkers in breast and colon cancer: Differentially breast and bolon 
proteomic profiling revealed several proteins involved in common pathways among the type of 
cancer. The important role of MMPs in tumorigenesis was confirmed by our observations regarding 
their major expressions in cancer tissues compared to the normal tissues. 
Prognostic biomarkers in breast and colon cancer: Among the differentially expressed proteins 
between normal-tumor and liver metastasis, Cathepsin D expression was further analyzed as 
prognostic factor in CRC. Moreover, integrating results obtained by bioinformatics analysis 
performed on breast cancer gene expression dataset confirmed the important role of S100 proteins 
in breast cancer progression. 
Cytotoxic effects of silver nanoparticles (AgNPs) biosynthesized from KO in SK-BR3 breast cancer 
cell line: The most important effects were obtained by aerobically AgNPs-EPS treatment, due to the 
major release of Ag+1, as verified by voltammetry analysis. Morphological alteration were 
consistent with apoptotic features. Proteomic analysis showed modulation of several proteins 
related to oxidative stress and apoptotic and mitochondrial pathways. 
Conclusions: Conclusively, the present study contribute to the implementation of the panel of new 
proteomic biomarkers useful for diagnostic and prognostic applications in breast and colon cancer, 
providing new informations about the effects of the biosynthesized Ag-NPs-EPS on breast cancer 
cells. 
